Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
---|---|---|---|---|---|---|
Operating Expenses | $28.2M | $52.1M | $355.7M | $115.2M | $104.9M | $130.6M |
Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
---|---|---|---|---|---|---|
% growth | 59.0 0.0% | 79.6 34.8% | 111.7 40.4% | 150.3 34.6% | 174.5 16.1% | 201.6 15.5% |
Cost of Goods Sold (COGS) | 17.0 | 21.4 | 31.8 | 47.1 | 57.6 | 64.9 |
% margin | 42.1 71.3% | 58.2 73.2% | 79.9 71.5% | 103.2 68.7% | 116.9 67.0% | 136.7 67.8% |
Operating Expenses | 28.2 | 52.1 | 355.7 | 115.2 | 104.9 | 130.6 |
Research & Development Expenses (R&D) | 4.1 | 6.3 | 153.4 | 17.2 | 19.9 | 26.7 |
Selling, General & Administrative Expenses (SG&A) | 24.1 | 45.8 | 202.3 | 98.1 | 85.1 | 103.9 |
% margin | 13.9 23.5% | 6.1 7.6% | (275.9) (247.0%) | (12.0) (8.0%) | 11.9 6.8% | 6.2 3.1% |
Interest Income | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 1.7 |
Interest Expense | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 0.0 |
Pre-tax Income | 13.1 | 4.5 | (281.7) | (12.2) | 11.5 | 7.4 |
% effective tax rate | 0.5 3.7% | 0.4 9.6% | 0.6 (0.2%) | 1.1 (8.8%) | 2.2 19.4% | 4.6 61.8% |
% margin | 12.7 21.4% | 4.1 5.1% | (282.2) (252.7%) | (13.3) (8.8%) | 6.0 3.5% | 2.8 1.4% |
EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.10 | 0.02 |
Diluted EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.07 | 0.01 |
% margin | 15.0 25.5% | 8.4 10.5% | (271.9) (243.4%) | (5.6) (3.7%) | 21.9 12.6% | 6.2 3.1% |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of today, Enfusion, Inc.'s last 12-month Operating Expenses is $130.6M, based on the financial report for Dec 31, 2024 (Q4’2024).
Over the last year, Enfusion, Inc.'s Operating Expenses growth was 24.4%. The average annual Operating Expenses growth rates for Enfusion, Inc. have been 28.1% over the past three years, 75.9% over the past five years.
Over the last year, Enfusion, Inc.'s Operating Expenses growth was 24.4%, which is higher than industry growth of (0.1%). It indicates that Enfusion, Inc.'s Operating Expenses growth is Bad.